Below are Freedom of Information Act (FOIA) requests filed by KEI related to issues concerning the coronavirus/COVID-19 pandemic. This page will be updated as we file requests and receive responses. Department of Health and Human Services Centers for Disease… Continue Reading
On 12 October 2022, Knowledge Ecology International (KEI) published a briefing note on the U.S. federal government FAR 52.227-1 authorizations (for non voluntary use of patents) disclosed in 166 SEC exhibits. KEI Briefing Note 2022:2, Federal government FAR 52.227-1 authorizations… Continue Reading
Since the COVID 19 Pandemic began, there has been a spirited debate over patent rights, including a highly publicized 20 month debate over a proposed WTO waiver on intellectual property rights. During that time a handful of countries have taken… Continue Reading
ACTIV The National Institutes of Health (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, to develop treatments and vaccines. Coordinated by the Foundation for the National Institutes of Health (FNIH), with the NIH and sibling agencies in the… Continue Reading
(For more resources, please see our page on molnupiravir.) Knowledge Ecology International (KEI) has obtained a copy of the $1.2 billion contract between the U.S. government and Merck to advance purchase 1,696,629 treatment courses of molnupiravir, an investigational COVID-19 drug… Continue Reading
Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) on Friday July 9, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific… Continue Reading
A $265 million COVID-19 vaccine manufacturing contract between the Department of Health and Human Services (HHS) and the Texas A&M University System (TAMUS) to manufacture the Novavax and other COVID-19 vaccines demonstrates that a manufacturing facility can be retrofitted to… Continue Reading
On March 31, 2020, KEI received a copy of the contract between Johnson & Johnson (“J&J”) and the Department of Health and Human Services (HHS) for the development of J&J’s COVID-19 vaccine.The contract, which is now valued at $1.3 billion,… Continue Reading
On March 1, 2021, KEI obtained a copy of the binding term sheet between Pfizer/BioNTech and the Dominican Republic for the supply of their COVID-19 vaccine in the country. The document, requested via the freedom of information law in the… Continue Reading
Moderna has attached three COVID-19 related contracts as exhibits to its SEC 10-Q form for the quarterly period ending in October 2020. The first is the contract between the Department of Health and Human Services (HHS) and Moderna for the… Continue Reading